Millie
your market intelligence analyst
Search Results
143 results
Your search is now limited to «Bristol-Myers Squibb» expert search.
NASDAQ 10/11/2019 08:45
Bristol-Myers Squibb (BMY) is on the list of such stocks currently recommended by our proprietary system.
More from NASDAQ:
Business Wire 10/08/2019 06:59
Bristol-Myers Squibb will provide notice of any such extension in advance of the Expiration Date.
More from Business Wire:
Seeking Alpha 10/03/2019 10:12
Bristol-Myers Squibb derives about two-thirds of its revenue from two of its drugs, the cancer therapy Opdivo and the anticoagulant Eliquis.
More from Seeking Alpha:
Pharmafile 10/02/2019 05:58
While objective responses rates were similar, with 19% for Opdivo and 22% for chemo, BMS’ drug was shown to increase the median duration of response by 6.9 months compared to 3.9 months with chemo.
More from Pharmafile:
Reuters.com 09/30/2019 19:01
A federal judge on Monday dismissed a proposed shareholder class action against Bristol-Myers Squibb Co alleging the drugmaker overstated the likelihood of success of a clinical trial for an anti-cancer drug.
More from Reuters.com:
PMLiVE 09/30/2019 04:53
These results build upon the long-term clinical data in first-line melanoma and renal cell carcinoma demonstrating the benefit of combining Yervoy and Opdivo compared to standard of care," said BMS’ head of oncology development Fouad Namouni.
More from PMLiVE:
ENDPOINTS 09/28/2019 10:37
Banking on Opdivo/Yervoy combo, Bristol-Myers Squibb teases out Checkmate-227 again at ESMO – Endpoints News.
More from ENDPOINTS:
PharmTech.com 09/28/2019 04:56
The Swords facility currently manufactures APIs for a number of medicines including Bristol-Myers Squibb’s and Pfizer’s Eliquis.
More from PharmTech.com:
FierceMedicalDevices 09/27/2019 08:13
As Celgene gradually phases into parent company Bristol-Myers Squibb, this is leaving little room at the inn for some of the top execs.
More from FierceMedicalDevices:
FiercePharmaManufacturing 09/27/2019 04:38
Bristol’s Opdivo-Yervoy pairing helped newly diagnosed patients live longer than chemotherapy alone, the company reported Saturday at the European Society for Medical Oncology Congress.
More from FiercePharmaManufacturing:
Zacks.com 09/23/2019 14:28
Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers Squibb (BMY), Lockheed Martin (LMT) and Alphabet (GOOGL.
More from Zacks.com:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications